Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imrecoxib for postoperative pain after total knee arthroplasty
ChiCTR-IPR-17013969Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of imrecoxib in postoperative pain (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Total tramadol use at 96 hours after surgery. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
imrecoxib
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR-IPR-17013969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17013969.